ArticleTransboundary and emerging diseases2023
Estimating the Importation Risk of Mpox Virus in 2022 to Hong Kong, China.
Article in Transboundary and emerging diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
International air travel has been recognized as a crucial factor in the cross-regional transmission of monkeypox (now known as mpox) since this disease rapidly spread across the globe in May 2022. On September 6, 2022, Hong Kong SAR (HK) reported its first imported mpox case with travel history of the United States (US), Canada, and the Philippines. In this study, we estimated the importation risk to HK from 25 international departure regions from May 1 to September 6, 2022, based on the prevalence of presymptomatic mpox cases in the study regions, and time-varying flight mobility evaluated by aggregating multiple open-access air travel datasets (e.g., OpenSky and Aviation Edge). The results of the study indicated that during the study period, the highest risk of mpox importation was from the US, at 63% (95% CI: 32% and 95%), followed by the United Kingdom (UK) and Canada, with risks of 29% (95% CI: 10% and 63%), and 17% (95% CI: 8% and 32%), respectively. The importation risk of mpox from the US and Canada was substantially higher than from the other regions, which was aligned with the travel history of the first reported case in HK. Our study introduces a simplified computational method that estimates the risk of importation mpox virus by combining air travel mobility, disease prevalence, and observed real-world scenarios to achieve accurate outcome estimates. Estimating the cross-regional importation risk of mpox would be beneficial in designing and adjusting inbound measures appropriately, which are essential for emergency public health policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.